Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors. A stock split doesn't change the overall market value of a company or anything fundamental -- but through the issuance of more shares to current holders, it lowers the per-share price.Since stock spl ...

If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors. Every three months, the regulator has everyone with more than $100 million under management share their trading details with the public on a Form 13F filing.One billionaire investor whom investors of all sizes follow closely is Philippe Laffont of Coatue Management. Known for investing in a combination of tech and healthcare stocks, Laffo ...

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory.  Eli Lilly (LLY -1.38%) and Novo Nordisk (NVO -0.32%) have attracted a lot of attention over the past two years thanks to their advances in the weight loss therapy market. Both companies are longtime leaders in the pharmaceutical industry and ...

Industry Overview - The healthcare industry has shifted focus from COVID vaccines to weight loss as the next major theme [2] - Eli Lilly and Novo Nordisk are leading players in the GLP-1 agonist market for diabetes treatment and chronic weight management [2] - The weight loss market represents a significant growth opportunity, with Lilly's market value exceeding Pfizer, Moderna, and J&J combined [14] - Novo Nordisk has become the most valuable company in Europe, surpassing LVMH Moët Hennessy [14] Company Comparison - Eli Lilly's Zepbound demonstrated superior weight loss results compared to Novo Nordisk's Wegovy, with 20% vs 14% average body weight reduction [4] - Zepbound showed better performance in secondary endpoints, with 32% of patients losing one-quarter of body weight compared to 16% for Wegovy [4] - Novo Nordisk's CagriSema achieved 22.7% average weight loss, slightly better than Zepbound but with only 40% of patients reaching the 25% target [5][19] - Novo Nordisk's stock experienced a significant 28% drop following the CagriSema trial results [10] Eli Lilly's Business Profile - Eli Lilly has a diverse medical portfolio beyond weight loss, including treatments for cancer, plaque psoriasis, Alzheimer's disease, and eczema [6][11] - The company's weight loss operation is fast-growing and expected to bolster revenue and profit base [16] - Eli Lilly is well-positioned to gain momentum in the weight loss market while maintaining leadership in the pharmaceutical industry [17] Novo Nordisk's Business Profile - Novo Nordisk's Ozempic is FDA-approved for diabetes treatment, while Wegovy is primarily prescribed for obesity care [15] - The company faced challenges with its latest weight loss candidate, CagriSema, which showed only marginal improvement over Zepbound [19] Investment Perspective - Eli Lilly is considered a superior investment opportunity compared to Novo Nordisk due to its progress in weight loss and diverse medical portfolio [1][12] - The company is viewed as a clear-cut winner in the pharmaceutical sector for long-term investors [13][17]

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.The drug is to be paired with a reduced-calorie diet and increased physical activity, the FDA noted.Sally Seymour, M.D., director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluati ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Key TakeawaysEli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.Over a year, 50% of patients in one trial reported that their sleep apnea symptoms went away. Eli Lilly's (LLY) Zepbound has received Food and Drug Administration (FDA) approval as a treatment for obstru ...

Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country. LLY is up 1.7% at $480.55 at last glance, while shares of rival ResMed Inc (NYSE:RMD), which creates continuous positive airway pressure (CPAP) devices for sleep apnea, was last seen down 5% at $225.44 after the news. On the charts, LLY posted a much-needed rebound last sessi ...

These three stocks, which are at or near the top of their respective industries, just increased dividends by double-digit percentages. Below, I’ll reveal how much these companies are paying out to shareholders now. I’ll also touch on notable share buyback news. Plus, I’ll provide an update on key proposed legislation that investors should be aware of regarding one of these companies. Get Mastercard alerts:PACCAR: +4% Yield Makes It One of the Top Dogs for Industrial Dividends PACCAR Dividend PaymentsDividen ...

Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Dec. 20, 2024. The video was published on Dec. 22, 2024. ...